




Multi-specific T Cell Engagers for Immune Reset in Autoimmunity and Targeted Cell Elimination in Cancer

Luis Borges, PhD - Founder & CEO
luis@artemiatx.com

Differentiated Multi-Specific T Cell Engagers for Autoimmunity and Cancer

T cell redirection to eliminate target cells



Artemia Tx TCE Platform

- **Multi-specific targeting (vs bi-specifics)**
→ enhanced efficacy and reduced antigen escape
- **Tuned CD3 activity**
→ optimized balance of potency and safety
- **Deep depletion of antibody producing cells in autoimmunity**
→ deeper immune reset vs anti-CD20
- **Off-the-shelf biologic (vs CAR-T)**
→ scalable, no lymphodepletion, outpatient use

Artemia Therapeutics Pipeline

Program	Indication	Therapeutic Strategy	Stage
ATX-101 (Lead Program)	Autoimmunity	Deep depletion of antibody-producing cells to enable immune reset	Preclinical → Lead selection
ATX-201	Oncology	Multi-antigen targeting to prevent tumor escape in hematologic malignancies	Preclinical → Lead optimization

- **Modular multi-specific T cell engager platform**
 - Reuse of selected platform components enables rapid generation of distinct autoimmunity and oncology programs
- **Seed financing supports advancement of both programs to key milestones (~15–18 months):**
 - **ATX-101:** Lead candidate selection
 - **ATX-201:** Discovery and lead optimization

Why Autoimmunity First

Rapid POC, Large Markets, Potential for Cures

- **70M+ patients worldwide**; no curative therapies
- **Current therapies: chronic immuno-suppression** with limited durability
- **Deep immune reset offers potential cures**
- **Fast PoC (3–6 months readouts)** than oncology trials
- **Initial disease indications:** SLE, Lupus Nephritis, Myasthenia Gravis, Sjögren's disease
- **Selective expansion:** niche indications with limited competition and strong biological fit



Artemia Tx Sits in a Large Whitespace Combining Best-in-Class Safety and Efficacy


Our Innovation & Advantages

- **Purpose-built multi-specific TCEs** → designed for autoimmunity and full depletion of pathogenic cells in the blood and tissues
- **Tunable dosing** → broader safety window
- **Off-the-shelf, cost-effective, and outpatient-ready** → broader access for patients and community care settings

Competitive Landscape

- **CAR-T cells** → constrained by complex manufacturing, lymphodepletion, and high costs
- **Antibodies** (e.g., rituximab) → partial efficacy, no durable immune reset
- **Repurposed oncology TCEs** → narrower safety margins

Artemia TCEs occupy a unique efficacy-safety whitespace



Artemia TCEs are purpose-built for autoimmunity, not repurposed from oncology.

Focused Execution and Capital-Efficient Value Creation

Lean Hybrid Development Model	Focused Execution	Milestone-Driven Capital Deployment
<p>Core, value-driving studies executed in-house to maintain scientific control</p> <p>Leverage CROs/CDMOs to accelerate development and minimize infrastructure</p> <p>Nona Biosciences and Abkyu agreements executed; work underway</p>	<p>ATX-101 prioritized to reach lead selection as a key value inflection</p> <p>ATX-201 advanced in parallel through binder discovery and lead optimization</p> <p>Modular platform enables efficient expansion beyond initial programs</p>	<p>Capital deployed to reach key milestones:</p> <ul style="list-style-type: none">• ATX-101 lead selection• ATX-201 lead optimization• Platform validation <p>Positions Artemia for IND-enabling studies + Phase I study)</p>

Clear path to clinical value inflection through focused execution and capital efficiency

\$5-6M Seed to Drive Value Inflection

Raising \$5–6M Seed Financing

15–18 months to value inflection points

Positions Artemia Tx for Series A

IND-enabling and Phase I initiation
Clinical proof-of-concept
Continued pipeline expansion

Use of Proceeds → Key Value Inflexion

ATX-101: Lead selection

ATX-201: Lead optimization



Platform: Validation of multi-specific TCE

Team: Core team build-out

Seed Round Delivers: ATX-101 lead candidate + ATX-201 progression + validated TCE platform

+

Three-Year Development Roadmap for ATX-101 and ATX-201



Experienced Founding Team

50+ years of experience advancing biologics and T cell therapies from concept to clinic



Luis Borges, PhD - Founder & CEO



Former CSO: Century Tx, Shinobi Tx, Metagenomi, Cell Medica

SVP of Research: Five Prime Therapeutics

Amgen: Led the development of the second-generation BiTE (T cell engager) platform

Immunex: immunology and immunotherapy foundation



Liam Campion - Co-founder & VP of Pharmacology



Former Director, In-vitro Pharmacology and Analytical Development - Century Tx

Prior experience: Janssen/Centocor- biologics from discovery to IND

Advisory Board: being assembled with leading experts in autoimmunity and T cell engagers

Why Artemia, Why Now

A Timely Opportunity in Immune Reset

Autoimmunity is ready for deeper immune reset

Validated B-cell biology and persistent unmet need create a major opening for next-generation therapies

TCEs are being redefined beyond oncology

Advances in tuning and target selection enable safer applications in autoimmune disease

Artemia Tx is built for this moment

Dual-lineage targeting, CD3 tuning, and a modular platform support differentiated programs in autoimmunity and MM

Near-term milestones create clear value inflection

Seed funding advances ATX-101 to lead selection, positioning the company for IND-enabling and FIH in Series A

Artemia Tx: From chronic suppression to durable immune reset

Thank you!

Luis Borges, PhD - Founder & CEO
luis@artemiatx.com